United States: Divided Infringement Challenges For Personalized Medicine

On remand from the U.S. Supreme Court, the U.S. Court of Appeals for the Federal Circuit last month held in Akamai Tech. Inc. v. Limelight Networks Inc. that "direct infringement liability of a method claim under 35 U.S.C. Section 271(a) exists when all of the steps of the claim are performed by or attributed to a single entity." In addition, the Federal Circuit ruled that direct infringement can be found in a multi-party situation that involves "a principal-agent relationship, a contractual relationship or in circumstances in which parties work together in a joint enterprise functioning as a form of mutual agency." However, the Federal Circuit did not specifically address the scope of "joint enterprise" liability, as not being before it given the facts of the case.

The result of this holding is that, after a detour to the Supreme Court, the Federal Circuit has essentially restored the holding of Muniauction Inc. v. Thomson Corp., 532 F.3d 1318 (Fed. Cir. 2008). In that case, the Federal Circuit had held that a defendant is not liable for direct infringement if the defendant does not exercise control or direction over its customers' performance of those steps of the claim the defendant does not itself perform. It follows that the value of drafting method claims that do not run afoul of the original Muniauction holding is once again greatly elevated and puts increased pressure on patent prosecutors and patent applicants to obtain such issued claims, assuming that such claims can be drafted and still meet the statutory requirements of patentability.

Within the personalized medicine space, method claims are oftentimes drafted in a manner that follows at least a two-step formula. The first step typically requires obtaining a dataset having data representing multiple biomarkers from a subject of interest. This step is generally expressed as either a digital step or a physical assay in a laboratory setting. Following the first step, the second step typically requires modifying the dataset in some manner via an algorithm to produce a score that is more informative of a particular subject state than any of the individual data points within the dataset. This sets up a situation with the potential for divided infringement challenges or loopholes in view of the recent Akamai holding as each step could be performed by different parties, neither of which exercises any direction or control over the other.

For example, if the first step of a method claim is a physical assay step, an independent laboratory could perform this physical assay independent of a distinct data analytics company that combines the dataset from the independent laboratory to produce a useful score, which is then reported to the patient, e.g., by a genetic counselor. As a result, the independent laboratory and data analytics company combine to perform the claimed method, but may not be held liable for claim infringement under Akamai. Because of this divided infringement loophole, the patent applicant in the above example would prefer to obtain an issued method claim that maintains the first step as a digital, rather than physical, step, since such a method claim is much less likely to involve more than one party performing its steps; avoiding the divided infringement problem entirely.

The impact of the Akamai holding on prosecution of personalized medicine patent applications at the U.S. Patent and Trademark Office will be particularly challenging given the recent Section 101 jurisprudence and related patent office guidance. This jurisprudence and guidance set out a two-step framework for analyzing patent claims for subject matter eligibility. The first step asks if a claim is directed to a process, machine, manufacture, or composition. Assuming it is, the second step has two parts. The first part asks if the claim is directed to a judicial exception (a law of nature, a natural phenomenon, or an abstract idea). Then, if it is, the second part asks whether any element or combination of elements, in the claim is sufficient to ensure that the claim amounts to significantly more than the judicial exception.

Included among the explicit examples of abstract ideas in the guidance offered by the patent office is an algorithm. Thus, it has become relatively commonplace for patent applicants to receive a Section 101 rejection in personalized medicine cases having method claims that include an algorithm or language that is equivalent to an algorithm.

Common avenues offered by patent examiners to overcome such Section 101 rejections include conversion of a first digital step to a physical assay step to make the method claim more concrete; or inclusion of a new third step directed to treatment of the subject using the score outputted from the algorithm of the second step, e.g., to direct the treatment regimen. However, as noted above, such limitations in method claims increase the risk that the patent claims will not be enforceable against a single entity if multiple, unrelated, parties perform the various steps separate from one another. This places patent applicants in a difficult situation of choosing between an issued patent claim that is currently patent eligible but vulnerable to the above noted divided infringement loophole versus appealing or continuing to prosecute the Section 101 rejection in hopes of obtaining a better claim scope in the pending patent application at some point in the future.

Available options for each personalized medicine patent application to deal with a challenging situation such as this will vary greatly depending on the technology area, the technology itself, and the particular uses of the technology. However, one option that should at least be considered in cases involving multiple biomarker-based assays is pursuit of an independent method claim to the physical assay alone, e.g., only to the combined detection of the multiple biomarkers in a laboratory-based assay. Removal of the second step directed to the algorithm from the typical personalized medicine method claim is likely to remove the Section 101 rejection as it will remove the abstract idea from the claim, thus obviating the Section 101 rejection entirely. As a result, such a method claim directed to just the physical assay step is likely to be considered patent eligible and avoid the divided infringement loophole created by Akamai; though it may be more vulnerable to novelty or obviousness challenges depending on the specific content of any relevant prior art references.

The recent Akamai holding together with the Section 101 jurisprudence and guidance has substantially increased the challenges faced by patent applicants in obtaining issued patent claims that are both patent eligible and adequately protect their inventions. However, technology-dependent options exist to mitigate these challenges and should be fully considered before deciding on a particular patent portfolio strategy within the personalized medicine space.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
20 Jan 2019, Conference, California, United States

Since 2009, recognized as a vital cornerstone for all constituents of the healthcare and biotechnology community, PMWC provides an exceptional forum for the exchange of information about the latest advances in technology (e.g. DNA sequencing technology), in clinical implementation (e.g. cancer and beyond), research, and in all aspects related to the regulatory and reimbursement sectors.

20 Jan 2019, Conference, California, United States

Fenwick partner ​Kevin Kabler will be speaking at the IO Intellectual Property session (January 21 at 2pm).

21 Jan 2019, Speaking Engagement, California, United States

Now entering its fifth year, the Pocket Gamer Connects events series has grown to become the biggest and most influential mobile games conference in the west as well as th​e biggest games event overall in the UK and Helsinki.

 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions